Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Proficient Cultivating Devices for a Lovely and Useful Nursery in 2024 - 21st-ever disease gene fix, Alzheimer's blood test: 7 medical breakthroughs in 2025
- 315 skywatching events you won't want to miss in 2026
- 4'Hero' who wrestled gun from Bondi shooter named as Ahmed al Ahmed
- 510 Hints for an Effective New employee screening
- 7 Popular Vacation destinations In China
- 7 Fun Plans to Make Film Evenings Seriously Invigorating (You'll Cherish #5!)
- US EPA will reassess safety of herbicide paraquat, says its chief
- What is the 'Survivor 50' Challenge? Hidden immunity idols will be up for grabs in every U.S. state.
- Audits of 6 American Busssiness Class Flights
- Antimatter took to the road for the very first time. Here’s why it matters
- Ghassan Al-Duhaini to replace Abu Shabab as Popular Forces leader in Gaza
- Ukrainian man arrested in Germany on suspicion of spying for Russia
- Video Conferencing Instruments for Virtual Gatherings
